Viking Therapeutics Stock Price Analysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Source: NASDAQ.COM
- Stock Performance: Viking Therapeutics, Inc. ended the recent trading session at $37.48, reflecting a -3.92% change from the previous day, although this decline was less than the S&P 500's loss of 0.22%, indicating relative resilience in its stock performance.
- Monthly Gain: The company's shares have gained 33.19% over the past month, significantly outperforming the Medical sector's 6.47% increase, suggesting strong market performance and heightened investor confidence.
- Earnings Forecast: The upcoming earnings report is expected to show an EPS of -$1.21, representing a 108.62% decline from the same quarter last year, highlighting the company's profitability challenges and market concerns about its future performance.
- Analyst Rating: Currently, Viking Therapeutics holds a Zacks Rank of #4 (Sell), with its industry positioned in the bottom 37% of the Zacks Industry Rank, signaling overall industry weakness and caution for investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VKTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VKTX
Wall Street analysts forecast VKTX stock price to rise
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 38.710
Low
70.00
Averages
97.00
High
125.00
Current: 38.710
Low
70.00
Averages
97.00
High
125.00
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vertex's $10B Crinetics Acquisition Sparks Biotech M&A Speculation
- M&A Activity Revived: Vertex's acquisition of Crinetics for $10 billion at $85 per share, representing a 102% premium, not only strengthens Vertex's foothold in rare endocrine diseases but also ignites speculation around VKTX and BCRX, leading to a broad rally in biotech stocks.
- VKTX's Positive Outlook: Viking Therapeutics saw a 9% stock increase post-announcement, with analysts projecting a 12-month target of $92.58, indicating a 120% upside, reflecting strong market confidence in its obesity drug VK2735, especially with upcoming Q3 maintenance data as a key catalyst.
- BCRX's Clear Benefits: BioCryst's shares rose 8%, with a 12-month target of $21.90 implying a 99% upside, bolstered by strong performance from its rare disease products Orladeyo and Navenibart, enhancing its competitive position in the market.
- Investor Sentiment Shift: Retail interest in VKTX and BCRX surged, with VKTX sentiment flipping from bearish to bullish as message volume jumped 400%, while BCRX sentiment turned extremely bullish from neutral, indicating strong investor interest and confidence in both stocks.
See More
Investment Outlook on Genetic Engineering and Weight Loss Innovations
- CRISPR Market Performance: CRISPR Therapeutics' stock is priced at $59.60, down 3.70% from the previous day, with a market cap of $6 billion; despite a 90% revenue decline due to the transition from one-time milestone payments to long-term commercial revenue, it highlights both challenges and potential in the gene therapy market.
- Viking Clinical Progress: Viking Therapeutics' stock is at $41.21, up 6.46%, yet it generated no revenue in FY 2025 with a net loss of approximately $359.6 million, reflecting high R&D costs in obesity and metabolic diseases and uncertainty in future commercialization.
- Risk and Dependency: CRISPR relies on Vertex Pharmaceuticals for 60% of its profits and faces intellectual property disputes that could impact financial sustainability, while Viking's dependence on Ligand Pharmaceuticals' licensing agreement poses a risk of halting its development programs, indicating vulnerabilities in both business models.
- Market Outlook Comparison: CRISPR's Casgevy treatment is globally approved, with projected sales exceeding $2 billion by 2029, while Viking is not expected to generate revenue until 2028; despite the vast GLP-1 drug market, Viking faces challenges in a competitive landscape.
See More
Viking Therapeutics Clinical Trial Outlook Analysis
- Market Competition Analysis: Viking Therapeutics' VK2735, a dual GLP-1/GIP agonist, faces significant competition from Eli Lilly and Novo Nordisk, whose drugs dominate the weight loss market, highlighting both challenges and opportunities for VK2735 in capturing market share.
- Unique Therapeutic Advantage: VK2735's dual formulation allows for rapid weight loss via injection followed by oral maintenance, achieving a notable 14.7% weight reduction in 13 weeks, which could appeal to patients seeking quicker results compared to competitors' offerings.
- Clinical Trial Progress: Viking is conducting a 19-week maintenance study, with phase 3 results for subcutaneous VK2735 expected in mid-2027 and oral dosing results anticipated in 2028, necessitating patience from investors as they await critical data.
- Investor Confidence and Risks: Despite a 20% discontinuation rate due to adverse events, market sentiment remains optimistic about VK2735's prospects, particularly if maintenance trial results are favorable, potentially attracting acquisition interest from larger pharmaceutical companies and enhancing the company's value.
See More
Comparative Investment in Gene Editing and Metabolic Medicine
- CRISPR's Market Position: CRISPR Therapeutics leads in gene editing, recently achieving its first product approval for rare blood disorders, yet its fiscal 2025 revenue of $3.5 million reflects a nearly 90% decline from the previous year, highlighting risks associated with its reliance on partnership-driven revenue.
- Viking's Clinical Challenges: Viking Therapeutics focuses on therapies for metabolic and endocrine disorders, reporting no revenue in fiscal 2025 and a net loss of approximately $359.6 million, indicating high risks associated with its clinical pipeline investments and dependence on Ligand Pharmaceuticals' licensing agreement, which could jeopardize drug development.
- Financial Health Comparison: CRISPR's current ratio stands at 13.3, indicating strong short-term solvency, but its free cash flow of negative $345.9 million underscores ongoing financial losses; conversely, Viking's current ratio of 9.3 and zero debt suggest a healthier financial structure, albeit with significant operational losses.
- Investment Outlook Assessment: While CRISPR's high valuation with a forward P/E of 19.1 contrasts with Viking's 17.7, both companies exhibit substantial growth potential in the biotech market, yet CRISPR's minimal sales, despite being small, render it more appealing to investors compared to Viking's pre-revenue status.
See More
Investment Outlook for CRISPR and Viking Therapeutics
- CRISPR Financial Challenges: CRISPR Therapeutics reported approximately $3.5 million in revenue for fiscal 2025, a nearly 90% decline year-over-year, with a net loss of about $581.6 million, highlighting the volatility of biotech revenues and increasing financial sustainability risks due to reliance on its partnership with Vertex Pharmaceuticals.
- Viking Clinical Investments: Viking Therapeutics reported no revenue for fiscal 2025, with a net loss of approximately $359.6 million as it heavily invests in its clinical pipeline for obesity and metabolic diseases; despite its zero-debt financial status, it faces uncertainties regarding regulatory approvals.
- Market Competition Analysis: CRISPR leads in gene editing with a high valuation but has achieved a breakthrough treatment for sickle cell disease, while Viking remains in the clinical stage without revenue, presenting higher investment risks.
- Investor Considerations: While both companies operate in high-growth sectors, CRISPR's sales performance makes it more attractive to investors, whereas Viking's prospects depend on its licensing agreement with Ligand Pharmaceuticals, where any changes could significantly impact its drug development timeline.
See More
Viking's VK2735 Shows Significant Weight Loss Potential
- Clinical Trial Progress: Viking Therapeutics' VK2735 demonstrates a peak weight loss of 14.7% in phase 2 trials, achieving this in just 13 weeks, significantly outperforming competitors, which may attract acquisition interest from larger pharmaceutical companies to expedite development.
- Dual Formulation Advantage: As a dual GLP-1/GIP agonist, VK2735 can initially be administered via injection for rapid weight loss and later switched to oral maintenance, providing a more convenient experience that could enhance patient adherence and market competitiveness.
- Safety Challenges: Despite VK2735's promising weight loss results, the safety data from the phase 2 oral trial raises concerns, with a 20% discontinuation rate due to adverse events in the treatment group, compared to 13% in the placebo group, potentially affecting future market acceptance.
- Future Outlook: Viking is conducting a 19-week maintenance study, with phase 3 results for subcutaneous dosing expected in mid-2027; if results are favorable, this could boost investor confidence and drive stock price appreciation.
See More
Vertex's $10B Crinetics Acquisition Sparks Biotech M&A Speculation
- M&A Activity Revived: Vertex's acquisition of Crinetics for $10 billion at $85 per share, representing a 102% premium, not only strengthens Vertex's foothold in rare endocrine diseases but also ignites speculation around VKTX and BCRX, leading to a broad rally in biotech stocks.
- VKTX's Positive Outlook: Viking Therapeutics saw a 9% stock increase post-announcement, with analysts projecting a 12-month target of $92.58, indicating a 120% upside, reflecting strong market confidence in its obesity drug VK2735, especially with upcoming Q3 maintenance data as a key catalyst.
- BCRX's Clear Benefits: BioCryst's shares rose 8%, with a 12-month target of $21.90 implying a 99% upside, bolstered by strong performance from its rare disease products Orladeyo and Navenibart, enhancing its competitive position in the market.
- Investor Sentiment Shift: Retail interest in VKTX and BCRX surged, with VKTX sentiment flipping from bearish to bullish as message volume jumped 400%, while BCRX sentiment turned extremely bullish from neutral, indicating strong investor interest and confidence in both stocks.
See More
Investment Outlook on Genetic Engineering and Weight Loss Innovations
- CRISPR Market Performance: CRISPR Therapeutics' stock is priced at $59.60, down 3.70% from the previous day, with a market cap of $6 billion; despite a 90% revenue decline due to the transition from one-time milestone payments to long-term commercial revenue, it highlights both challenges and potential in the gene therapy market.
- Viking Clinical Progress: Viking Therapeutics' stock is at $41.21, up 6.46%, yet it generated no revenue in FY 2025 with a net loss of approximately $359.6 million, reflecting high R&D costs in obesity and metabolic diseases and uncertainty in future commercialization.
- Risk and Dependency: CRISPR relies on Vertex Pharmaceuticals for 60% of its profits and faces intellectual property disputes that could impact financial sustainability, while Viking's dependence on Ligand Pharmaceuticals' licensing agreement poses a risk of halting its development programs, indicating vulnerabilities in both business models.
- Market Outlook Comparison: CRISPR's Casgevy treatment is globally approved, with projected sales exceeding $2 billion by 2029, while Viking is not expected to generate revenue until 2028; despite the vast GLP-1 drug market, Viking faces challenges in a competitive landscape.
See More
Viking Therapeutics Clinical Trial Outlook Analysis
- Market Competition Analysis: Viking Therapeutics' VK2735, a dual GLP-1/GIP agonist, faces significant competition from Eli Lilly and Novo Nordisk, whose drugs dominate the weight loss market, highlighting both challenges and opportunities for VK2735 in capturing market share.
- Unique Therapeutic Advantage: VK2735's dual formulation allows for rapid weight loss via injection followed by oral maintenance, achieving a notable 14.7% weight reduction in 13 weeks, which could appeal to patients seeking quicker results compared to competitors' offerings.
- Clinical Trial Progress: Viking is conducting a 19-week maintenance study, with phase 3 results for subcutaneous VK2735 expected in mid-2027 and oral dosing results anticipated in 2028, necessitating patience from investors as they await critical data.
- Investor Confidence and Risks: Despite a 20% discontinuation rate due to adverse events, market sentiment remains optimistic about VK2735's prospects, particularly if maintenance trial results are favorable, potentially attracting acquisition interest from larger pharmaceutical companies and enhancing the company's value.
See More
Comparative Investment in Gene Editing and Metabolic Medicine
- CRISPR's Market Position: CRISPR Therapeutics leads in gene editing, recently achieving its first product approval for rare blood disorders, yet its fiscal 2025 revenue of $3.5 million reflects a nearly 90% decline from the previous year, highlighting risks associated with its reliance on partnership-driven revenue.
- Viking's Clinical Challenges: Viking Therapeutics focuses on therapies for metabolic and endocrine disorders, reporting no revenue in fiscal 2025 and a net loss of approximately $359.6 million, indicating high risks associated with its clinical pipeline investments and dependence on Ligand Pharmaceuticals' licensing agreement, which could jeopardize drug development.
- Financial Health Comparison: CRISPR's current ratio stands at 13.3, indicating strong short-term solvency, but its free cash flow of negative $345.9 million underscores ongoing financial losses; conversely, Viking's current ratio of 9.3 and zero debt suggest a healthier financial structure, albeit with significant operational losses.
- Investment Outlook Assessment: While CRISPR's high valuation with a forward P/E of 19.1 contrasts with Viking's 17.7, both companies exhibit substantial growth potential in the biotech market, yet CRISPR's minimal sales, despite being small, render it more appealing to investors compared to Viking's pre-revenue status.
See More
Investment Outlook for CRISPR and Viking Therapeutics
- CRISPR Financial Challenges: CRISPR Therapeutics reported approximately $3.5 million in revenue for fiscal 2025, a nearly 90% decline year-over-year, with a net loss of about $581.6 million, highlighting the volatility of biotech revenues and increasing financial sustainability risks due to reliance on its partnership with Vertex Pharmaceuticals.
- Viking Clinical Investments: Viking Therapeutics reported no revenue for fiscal 2025, with a net loss of approximately $359.6 million as it heavily invests in its clinical pipeline for obesity and metabolic diseases; despite its zero-debt financial status, it faces uncertainties regarding regulatory approvals.
- Market Competition Analysis: CRISPR leads in gene editing with a high valuation but has achieved a breakthrough treatment for sickle cell disease, while Viking remains in the clinical stage without revenue, presenting higher investment risks.
- Investor Considerations: While both companies operate in high-growth sectors, CRISPR's sales performance makes it more attractive to investors, whereas Viking's prospects depend on its licensing agreement with Ligand Pharmaceuticals, where any changes could significantly impact its drug development timeline.
See More
Viking's VK2735 Shows Significant Weight Loss Potential
- Clinical Trial Progress: Viking Therapeutics' VK2735 demonstrates a peak weight loss of 14.7% in phase 2 trials, achieving this in just 13 weeks, significantly outperforming competitors, which may attract acquisition interest from larger pharmaceutical companies to expedite development.
- Dual Formulation Advantage: As a dual GLP-1/GIP agonist, VK2735 can initially be administered via injection for rapid weight loss and later switched to oral maintenance, providing a more convenient experience that could enhance patient adherence and market competitiveness.
- Safety Challenges: Despite VK2735's promising weight loss results, the safety data from the phase 2 oral trial raises concerns, with a 20% discontinuation rate due to adverse events in the treatment group, compared to 13% in the placebo group, potentially affecting future market acceptance.
- Future Outlook: Viking is conducting a 19-week maintenance study, with phase 3 results for subcutaneous dosing expected in mid-2027; if results are favorable, this could boost investor confidence and drive stock price appreciation.
See More
